In Vivo Anti-Tumor Activity of the PARP Inhibitor Niraparib in Homologous Recombination Deficient and Proficient Ovarian Carcinoma
Gynecologic Oncology - United States
doi 10.1016/j.ygyno.2016.08.328
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2016
Authors
Publisher
Elsevier BV